<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916106</url>
  </required_header>
  <id_info>
    <org_study_id>2018079</org_study_id>
    <secondary_id>S2020-YF-YBSF-0237</secondary_id>
    <nct_id>NCT04916106</nct_id>
  </id_info>
  <brief_title>Effect of Transcutaneous Electroacupuncture on Functional Abdominal Bloating/Distension</brief_title>
  <official_title>Effect of Transcutaneous Electroacupuncture on Patients With Functional Abdominal Bloating/Distension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional abdominal bloating/distension (FAB/D) is a common functional bowel disorder that&#xD;
      lacks effective treatment options. Transcutaneous electroacupuncture (TEA) as a new&#xD;
      therapeutic method has great effect on functional gastrointestinal diseases such as&#xD;
      functional dyspepsia and functional constipation. Research on TEA for FAB/D has not yet been&#xD;
      explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional abdominal bloating/distension (FAB/D) is a common functional bowel disorder that&#xD;
      lacks effective treatment options. Rome IV was introduced in 2016. Studies have shown that&#xD;
      bloating may affect about 30% general population and 96% of patients with functional&#xD;
      gastrointestinal disorders (FGID).Transcutaneous electroacupuncture (TEA) as a new&#xD;
      therapeutic method has great effect on functional gastrointestinal diseases such as&#xD;
      functional dyspepsia and functional constipation. Research on TEA for FAB/D has not yet been&#xD;
      explored. Thirty patients who fulfilled the Rome IV diagnostic criteria of FAB/D in the&#xD;
      department of the second affiliated hospital of Xi'an jiaotong University.Inclusion criteria&#xD;
      included: Symptoms of recurrent abdominal fullness, pressure, or a sensation of trapped gas&#xD;
      (bloating), and/or measurable (objective) increase in abdominal girth (distention) more than&#xD;
      6 month；the main symptoms appeared in the past 3 months；Not taking related drugs; aged 18-65&#xD;
      years old；From January 2020 to December 2021; Sign informed consent. All patients were&#xD;
      randomly assigned to 3 groups and received TEA at Zusanli (ST36) and Neiguan (PC6) with 3&#xD;
      diffrent parameter for 4weeks. The symptom severity score, abdominal girth, electrogastrogram&#xD;
      (ECG) and orocecal transit time (OCTT) were recorded at baseline and after 2-week treatment,&#xD;
      respectively. The symptom severity score、heart rate variability (HRV) 、rectal sensitivity and&#xD;
      intestinal flora were recorded at baseline and after 4-week treatment, respectively. Through&#xD;
      the comparison of the index before and after TEA treatment to identify optimal stimulation&#xD;
      parameters and explore its possible mechanism. The study was proved by the medical ethics&#xD;
      committee of the Second Affiliated Hospital of Xi'an jiaotong University.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom improvement rate</measure>
    <time_frame>after 1 month TEA treatment</time_frame>
    <description>the symptom severity score with VAS and abdominal girth measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of the normal gastric slow waves in electrogastrograph</measure>
    <time_frame>after 1 month TEA treatment</time_frame>
    <description>The percentage of the normal gastric slow waves in fasting 、fed states and the post-preprandial EGG power ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Orocecal ransit time</measure>
    <time_frame>after 1-month TEA treatment</time_frame>
    <description>the lactulose hydrogen breath test was used to evaluate the intestinal transit time and observe the presence or absence of excessive small intestinal bacteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate variability（HRV）</measure>
    <time_frame>after 1-month TEA treatment</time_frame>
    <description>Assessment of autonomic function with heart rate variability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flora structure</measure>
    <time_frame>after 1-month TEA treatment</time_frame>
    <description>an Illumina MiSeq Platform was used to sequence 16S ribosomal RNA (rRNA) gene of the total bacteria in fecal samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rectal sensitivity</measure>
    <time_frame>after 1-month TEA treatment</time_frame>
    <description>Rectal threshold for gas and defecation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma gastrointestinal peptide level</measure>
    <time_frame>after 1-month TEA treatment</time_frame>
    <description>CCK、SP、NPY、CGRP、Motilin</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Functional Abdominal Bloating/Distension</condition>
  <arm_group>
    <arm_group_label>One parameter TEA group for 4weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choose several acupoints,give 25Hz dilatational wave stimulation for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Another parameter TEA group for 4weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choose several acupoints,give 100 Hz dilatational wave stimulation for 4weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no TEA group 2 weeks, and the 2 parameters TEA for the next 2 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choose several acupoints, tape over the electrode but don't give electroacupuncture stimulation in the first 2 weeks, give 25Hz and 100Hz dilatational wave electroacupuncture stimulation in the next 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Electroacupuncture</intervention_name>
    <description>give diffrent parameter TEA treatment for 4 weeks.</description>
    <arm_group_label>Another parameter TEA group for 4weeks</arm_group_label>
    <arm_group_label>One parameter TEA group for 4weeks</arm_group_label>
    <arm_group_label>no TEA group 2 weeks, and the 2 parameters TEA for the next 2 weeks.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of Functional bloating/distension with Rome IV;&#xD;
&#xD;
          2. Aged 18-65 years old；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have taken drugs that may affect gastrointestinal motility in the past week;&#xD;
&#xD;
          2. Have taken antibiotics and probiotics in the past month;&#xD;
&#xD;
          3. The history of gastrointestinal surgery;&#xD;
&#xD;
          4. Helicobacter pylori is not cleared；&#xD;
&#xD;
          5. Pregnant and breastfeeding women;&#xD;
&#xD;
          6. Skin allergies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fei Dai</last_name>
    <phone>13772151298</phone>
    <email>daifei68@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yindi Chen</last_name>
    <phone>18119487105</phone>
    <email>daifei68@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The second affiliated hospital of xi'an jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Dai, MD</last_name>
      <phone>13772151298</phone>
      <email>daifei68@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yindi Chen</last_name>
      <phone>18119487105</phone>
      <email>593825787@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Bloating/Distension</keyword>
  <keyword>Transcutaneous electrical acupoint stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

